

***In Vitro Regulation of  
Growth, Differentiation and  
Survival of  
Leukemic CD5<sup>+</sup> B Cells***

**Stuart G. Tangye**

A thesis submitted for the Degree of

**DOCTOR OF PHILOSOPHY**

University of Technology, Sydney

1995.

### ***Declaration***

I certify that this thesis has not already been submitted for any degree and is not being submitted as part of candidature for any degree.

I also certify that this thesis has been written by me and that any help that I received in preparing this thesis, and all sources used, have been acknowledged.

A handwritten signature in black ink, appearing to read 'Stuart G. Tangye', written in a cursive style.

Stuart G. Tangye.

B. App. Sc. (Hons.)

### *Acknowledgements*

My first thank you goes to my supervisor, Professor Bob Raison. Bob not only allowed me to undertake my studies in his laboratory but also provided me with a great deal of his time, assistance and encouragement. Something that I am particularly grateful for was the amount of latitude Bob gave me with the direction that this project took. He always gave me enough rope, but never let me hang myself. So, many thanks Bob - it has been a pleasure and a privilege to work under your supervision.

I would also like to thank Dr. Kath Weston for being very helpful during various stages of this project, and for meticulously proof-reading this thesis. Thanks, Kath, also for the many stimulating discussions about B cells, cell culture and flow cytometry. Your support, enthusiasm and friendship have been invaluable and have contributed immensely to this work.

The Immunobiology Unit, UTS, has been a great place to work and many of its members, past and present, have been of assistance throughout the last 4 years. I would particularly like to acknowledge Grant Shoebridge who, despite being a molecular biologist, always took an interest in my project, was never afraid to ask me what was I doing and why, and was always willing to take a crash course in B cellology in order to understand my work. I would also like to thank Associate Professor Kevin Broady, Carolyn Woodlands, Nick dos Remedios and Jeanette Taverner for assistance at various times during the course of this project.

The N.S.W Cancer Council, Australasian Society for Immunology, UTS Vice-Chancellors Postgraduate travel fund and Bob all deserve thanks for

providing me with travel grants that enabled me to attend international conferences.

Outside of UTS, warm thanks go to my parents, family and friends for their continued support and interest over the years. Finally, none of this would have been possible without Karen who, for many years, has continued to be an eternal and invaluable source of patience, love, support and encouragement.

### ***Abstract***

B cell chronic lymphocytic leukemia (B-CLL) is a hematologic neoplasm characterised by the proliferation and accumulation of sIgM<sup>+</sup>/D<sup>+</sup> B cells that fail to progress to the final stages of B cell development. The malignant cells in B-CLL also express the pan-T cell antigen CD5, suggesting that CLL is a malignancy of the CD5<sup>+</sup> subset of B cells. Additional characteristics of the malignant clone include a low proliferative index, enhanced *in vivo* survival and constitutive expression of the anti-apoptosis oncoprotein bcl-2. The behaviour of leukemic CD5<sup>+</sup> B cells *in vitro* contrasts their arrested *in vivo* state. That is, despite the majority of cells being arrested in the G<sub>0</sub> phase of the cell cycle, the leukemic B cells are not irreversibly frozen as they can be induced to differentiate to Ig-secreting cells under appropriate *in vitro* conditions. Furthermore, leukemic CD5<sup>+</sup> B cells rapidly undergo death by apoptosis following *in vitro* culture. This thesis describes the requirements for *in vitro* activation of leukemic CD5<sup>+</sup> B cells, the characterisation of the events involved in apoptosis of these cells as well as the identification of various growth factors capable of modulating these events.

Stimulation of unfractionated peripheral blood lymphocytes (PBLs) from three patients with B-CLL with the phorbol ester PMA and the mitogens PHA and PWM resulted in significant increases in cell proliferation, RNA synthesis and IgM secretion when compared to unstimulated cell populations. PMA was the most potent inducer of IgM secretion and this occurred irrespective of the presence of residual T cells. PMA-induced proliferation and RNA synthesis were also independent of T cells. However, in the presence of T cells, these parameters of cellular activation were enhanced during *in vitro* culture. Thus, the inductive ability of PMA on leukemic CD5<sup>+</sup> B cells was independent of T cells. In

contrast, activation and differentiation of the leukemic CD5<sup>+</sup> B cells into IgM-secreting cells following culture with mitogens did not occur in the absence of T cells. Interestingly, co-stimulation of leukemic CD5<sup>+</sup> B cells with PMA and anti-Ig induced cellular responses that exceeded those induced by either activator alone. Thus, leukemic CD5<sup>+</sup> B cells from patients with B-CLL can be activated *in vitro* and differentiate in response to stimulation via both T cell-dependent and T cell-independent mechanisms.

Apoptotic cell death was characterised in purified leukemic CD5<sup>+</sup> B cells obtained from six B-CLL patients. All leukemic CD5<sup>+</sup> B cell populations entered an apoptotic pathway *in vitro* as evidenced by a reduction in cell size, loss of cell viability and fragmentation of DNA into multimers of ~180 base pairs. Following 24 hours of *in vitro* culture 24.0±16% of DNA was fragmented. After 8 days, the majority of DNA was fragmented, and fewer than 10% of cultured cells were viable. Examination of bcl-2 expression in the malignant B cells by flow cytometry revealed a unimodal pattern of expression in >85% of cells from each B-CLL patient prior to culture. During *in vitro* culture, bcl-2 expression became bimodal such that the B cells displayed a bcl-2<sub>high</sub> and bcl-2<sub>low</sub> phenotype. The level of expression by the bcl-2<sub>high</sub> cells was similar to that observed prior to *in vitro* culture, indicating that bcl-2 is down-regulated in apoptosing cells. Interestingly, despite this down-regulation, the overall number of cells positive for bcl-2 remained constant. This suggests that the enhanced survival of leukemic CD5<sup>+</sup> B cells *in vivo* is mediated by the sustained expression of bcl-2 and that additional mechanisms exist capable of overriding the protective effect of bcl-2 when bcl-2 is present at reduced levels.

Leukemic B cell apoptosis has previously been reported to be delayed or prevented by IL-4, IFN- $\gamma$  and IFN- $\alpha$ . These results were confirmed in this study where it was found that culture of leukemic CD5<sup>+</sup> B cells with IL-4 or IFN- $\gamma$  enhanced cell viability and delayed apoptosis in 6/6 and 5/6 populations of leukemic B cells, respectively. This function was also found to be shared by IL-2, IL-6, IL-13 and TNF- $\alpha$  as these cytokines enhanced cell viability and delayed apoptosis in some of the cell populations examined at a level similar to that observed for IL-4 and IFN- $\gamma$ . These cytokines may mediate their effect via the expression of bcl-2 as culture in the presence of IL-2, IL-4, IL-6, IL-13, IFN- $\gamma$  or TNF- $\alpha$  resulted in a higher percentage of cells displaying the bcl-2<sub>high</sub> phenotype, compared to unstimulated cells. Taken together, these results suggest that autocrine and/or paracrine growth loops may play a role in the pathogenesis of B-CLL and that cytokines that prevent apoptosis *in vitro* may be targets for treatment of this B cell malignancy.

***Publications arising from work presented in this thesis***

Tangye SG, Weston KM and Raison RL (1995). Phorbol ester activates CD5<sup>+</sup> leukemic B cells via a T cell-independent mechanism. **Immunol. Cell Biol.** 73: 44-51.

Tangye SG and Raison RL (1995). Leukemic CD5<sup>+</sup> B cell apoptosis: coincidence of cell death and DNA fragmentation with reduced bcl-2 expression. **Br. J. Haem.** 92: 950-953.



## TABLE OF CONTENTS

	PAGE Nº.
<b><i>Chapter 1: Introduction</i></b>	
<u>B Cell Development, Function and Differentiation</u>	2
B Cells as Immunoglobulin-Secreting Cells	2
B Cell Development	4
B Cell Activation, Proliferation and Differentiation	
<i>In vitro</i>	7
Activation via sIg	7
T Cell-Dependent B cell Activation	9
Activation via CD40	12
The Role of CD5 and its Ligand, CD72, in Cellular Activation	18
<u>CD5<sup>+</sup> B Cells</u>	19
Characteristics of CD5 <sup>+</sup> B Cells	19
Appearance during Ontogeny; Anatomical Location	19
Phenotype/Morphology	21
Origin of CD5 <sup>+</sup> B Cells	22
Secreted Immunoglobulin	23
<i>In vitro</i> Responses	26
Function of Normal CD5 <sup>+</sup> B Cells	27
<u>Chronic Lymphocytic Leukemia</u>	28
Characteristics of the Malignant Clone	28
<i>In vitro</i> Activation of Leukemic CD5 <sup>+</sup> B Cells	29
Phorbol Esters	30
Mitogens	32
Activation via Cell Surface Antigens	32
Cytokines	35
Isotype Switching by CLL B Cells	39

Heterogeneity of Leukemic B Cell	
Responses, <i>In vitro</i>	40
Cytokines Secreted by CLL B Cells	41
<u>Apoptosis</u>	42
Apoptosis in the Immune System	43
Genetic Regulation of Apoptosis	46
Bcl-2	46
Fas/APO-1/CD95	50
Apoptosis and Leukemic CD5 <sup>+</sup> B Cells	50
Expression of bcl-2 and Fas in CLL B Cells	53
<u>Aims of this Study</u>	55
<b>Chapter 2: Materials and Methods</b>	
Antibodies for Immunofluorescence	56
Reagents/Antibodies for Immunoassays	56
Mitogens	57
Cytokines and Related Antibodies	57
B-CLL Cells	57
Depletion of T Cells from CLL PBLs	58
Preparation of AET-treated SRBCs	58
Rosetting	59
Purification of T Cells from Normal Peripheral Blood	59
Surface Immunofluorescence	60
B Cell Cultures	61
Cell Proliferation and RNA Synthesis	61
Optimisation of Mitogen Concentrations	62
Activation via sIgM	62
Investigation of Leukemic B Cell Survival, <i>In vitro</i>	63
Co-culture with Allogeneic T Cells	63

Cytokine Cultures	64
Neutralisation of and Delayed Addition of Cytokines	64
Detection of Secreted Immunoglobulin	65
Detection of Binding of Secreted IgM to Mouse IgG	66
Determination of Cellular Viability	67
Determination of Apoptosis	67
Agarose Gel Electrophoresis	67
Apoptotic Nuclei	68
Expression of Bcl-2 Protein	69
SDS-PAGE and Western Blot Analysis	69
Immunofluorescence and Flow Cytometry	70
Treatment with Bcl-2 Antisense Oligonucleotides	71

### ***Chapter 3: In vitro Activation of Leukemic CD5<sup>+</sup> B Cells.***

<b>Introduction</b>	72
<b>Results</b>	
3.1. B-CLL Cell Phenotype.	74
3.2. Optimisation of <i>In vitro</i> Stimulation Conditions	79
3.3. Kinetic of CLL PBL Responses Following <i>In vitro</i> Stimulation	81
3.4. Development of Ig Isotype-Specific Immunoassays	86
3.5. Stimulation of CLL PBLs with Cellular Activators Induces IgM Secretion	89
3.6. PMA Induces Cellular Activation in the Absence of T Cells	96
3.7. T Cell Depletion of CLL PBLs Abrogates Mitogen-induced Activation and Differentiation	97
3.8. Effect of Residual T Cells on Leukemic B Cell Viability	99

3.9. Exogenous Cytokines Augment PMA-Induced Leukemic CD5 <sup>+</sup> B Cell Activation	101
3.10. Induction of Leukemic CD5 <sup>+</sup> B Cell Activation via Ligation of sIgM	104
3.11. Kinetics of Responses of Leukemic CD5 <sup>+</sup> B Cells to Anti- $\mu$ + PMA are Similar to PMA <sub>opt</sub> Alone	111
3.12. Anti- $\mu$ has no Effect on the Enhancement of Viability of Leukemic CD5 <sup>+</sup> B Cells Caused by PMA	116
3.13. Crosslinking sIgM Does not Enhance Differentiation to IgM Secretion	117
<b>Discussion</b>	119

#### ***Chapter 4: Characterisation of In Vitro Apoptosis of Leukemic CD5<sup>+</sup> B Cells***

<b>Introduction</b>	134
<b>Results</b>	
4.1. Phenotype of CLL B Cells.	136
4.2. Kinetics of Leukemic CD5 <sup>+</sup> B Cell Death, <i>In vitro</i>	136
4.3. Leukemic B Cells Undergo Spontaneous Apoptosis, <i>In vitro</i>	139
4.4. Characterisation of Apoptotic Cell Populations	142
4.5. Expression of Bcl-2 by Leukemic B Cells	149
i. SDS-PAGE/Western Blotting	149
ii. Immuno-flow Cytometry	152
4.6. Detection of bcl-2 Expression	154
4.7. Effect of Antisense Oligonucleotides on Viability and Bcl-2 Expression by <i>In vitro</i> Cultured Leukemic CD5 <sup>+</sup> B Cells	159
<b>Discussion</b>	164

**Chapter 5: Regulation of Leukemic CD5<sup>+</sup> B Cell Apoptosis In Vitro By Cytokines**

<b>Introduction</b>	171
<b>Results</b>	
5.1. Soluble Factors Secreted by Activated T Cells	
Enhance Leukemic CD5 <sup>+</sup> B Cell Survival	174
5.2. Effect of Cytokines on Viability of Leukemic CD5 <sup>+</sup> B Cells <i>In vitro</i>	176
5.3. Responsiveness to IL-2 Correlated with Expression of CD25	184
5.4. KAR B Cells Express CD80 and Respond to IL-13	184
5.5. IL-2, IL-4, IL-6, IL-13, IFN- $\gamma$ and TNF- $\alpha$ Reduce Apoptosis in Stimulated Leukemic CD5 <sup>+</sup> B Cells	187
5.6. Effect of Combinations of Cytokines on Viability of Leukemic CD5 <sup>+</sup> B Cells	196
5.7. Long Term Effects of Cytokines on Leukemic CD5 <sup>+</sup> B Cell Viability and Apoptosis	199
5.8. Requirements of Leukemic CD5 <sup>+</sup> B Cells for the Presence of Cytokines During <i>In vitro</i> Culture	206
5.9. The Signal Delivered by Cytokines is Insufficient to Induce Cell Proliferation	215
5.10. Expression of Bcl-2 by Cytokine-treated Leukemic CD5 <sup>+</sup> B Cells	217
<b>Discussion</b>	224
 <b>Summary and Conclusions</b>	 241
 <b>Bibliography</b>	 245

## LIST OF FIGURES

<b>Figure 1.1:</b> Characteristics of Developing B Cells	5
<b>Figure 3.1:</b> Phenotype of Unfractionated PBLs from CLL Patients.	75
<b>Figure 3.2:</b> Phenotype of T-Depleted CLL B Cell Preparations	76
<b>Figure 3.3:</b> Expression of sIg by CLL B Cells	77
<b>Figure 3.4:</b> Expression of Activation Antigens by CLL B Cells	78
<b>Figure 3.5:</b> Optimisation of PMA, PHA and PWM	80
<b>Figure 3.6:</b> PMA-induced Activation of Unfractionated PBLs and Purified B cells from B-CLL Patients.	82
<b>Figure 3.7:</b> Mitogen-Stimulated Leukemic B Cells and Residual T Cells Proliferate at a Similar Rate.	85
<b>Figure 3.8:</b> Development of Isotype-Specific Immunoassays.	87
<b>Figure 3.9:</b> Cross-Reactivity of IgM and IgG in the Isotype-Specific Immunoassays.	88
<b>Figure 3.10:</b> <i>In vitro</i> Activation of Leukemic CD5 <sup>+</sup> B Cells Induces IgM Secretion.	90
<b>Figure 3.11:</b> Light-chain isotype of IgM secreted by PMA-stimulated CLL PBLs	91
<b>Figure 3.12:</b> Binding of IgM Secreted by CLL B Cells to Mouse Ig.	93
<b>Figure 3.13:</b> Mitogenic-stimulation of MIL CLL PBLs Results in Secretion of IgG.	95

<b>Figure 3.14:</b> PMA Activation Induces Lymphoblastoid Transformation.	98
<b>Figure 3.15:</b> Mitogen Stimulation Enhances the Viability of CLL PBLs, but not T-depleted B Cells.	100
<b>Figure 3.16:</b> Exogenous Cytokines Enhance PMA-Induced Activation. of Leukemic B Cells	103
<b>Figure 3.17:</b> Anti- $\mu$ Synergises with PMA to Induce Proliferation of CLL PBLs.	105
<b>Figure 3.18:</b> Responses of Purified CD5 <sup>+</sup> Leukemic B Cells to Anti- $\mu$ and PMA.	106
<b>Figure 3.19:</b> Activation via sIgM is Enhanced with Increasing Concentrations of PMA	109
<b>Figure 3.20:</b> Kinetics of Proliferation and RNA Synthesis Induced by PMA and Anti- $\mu$ in Leukemic CD5 <sup>+</sup> B Cells	113
<b>Figure 4.1:</b> Kinetics of Leukemic CD5 <sup>+</sup> B Cell Death and Apoptosis.	138
<b>Figure 4.2:</b> Leukemic CD5 <sup>+</sup> B cells Undergo DNA Fragmentation <i>in vitro</i> .	141
<b>Figure 4.3:</b> Apoptosis is Accompanied By Reduced Forward Light Scatter	143
<b>Figure 4.4:</b> Characterisation of Apoptotic Cell Populations	144
<b>Figure 4.5:</b> Reduction in Cell Size Precedes Cell Death.	147

<b>Figure 4.6:</b> Detection of bcl-2 in Leukemic B Cells by SDS-PAGE and Western Blotting.	150
<b>Figure 4.7:</b> Optimisation of Detection of Bcl-2 by Immuno-flow Cytometry	153
<b>Figure 4.8:</b> Leukemic CD5 <sup>+</sup> B Cells Express High Levels of bcl-2	155
<b>Figure 4.9:</b> Kinetics of Reduction of Bcl-2 Expression by <i>In vitro</i> Cultured Leukemic CD5 <sup>+</sup> B cells.	156
<b>Figure 4.10:</b> Reduced bcl-2 Expression Correlates with Cell Death	157
<b>Figure 4.11:</b> Effect of Phosphothioate-treated Oligonucleotides on the Light Scattering Characteristics of Leukemic B Cells.	161
<b>Figure 5.1:</b> Soluble Factors Secreted by <i>In vitro</i> Activated T Cells Enhance Viability of Leukemic CD5 <sup>+</sup> B Cell	175
<b>Figure 5.2:</b> Optimisation of Cytokine Concentrations for Enhancement of Viability of Leukemic CD5 <sup>+</sup> B Cells	178
<b>Figure 5.3:</b> Effect of Cytokines on Leukemic B Cell Survival, <i>In vitro</i> .	182
<b>Figure 5.4:</b> Expression of CD25 by Leukemic CD5 <sup>+</sup> B Cells.	185
<b>Figure 5.5:</b> Expression of CD80 by Leukemic CD5 <sup>+</sup> B Cells	186
<b>Figure 5.6:</b> Effect of Cytokines on Death and Apoptosis in Different Leukemic CD5 <sup>+</sup> B Cells.	188
<b>Figure 5.7:</b> Cytokines do not Prevent Apoptosis in Leukemic CD5 <sup>+</sup> B Cells	191



<b>Figure 5.8:</b> Cytokines Prevent the Reduction in Cell Size that occurs in Apoptotic Leukemic CD5 <sup>+</sup> B Cells	194
<b>Figure 5.9:</b> Combinations of Cytokines do not Synergise to Further Enhance Viability of Leukemic CD5 <sup>+</sup> B Cell	197
<b>Figure 5.10:</b> Long Term Effects of Cytokines on Leukemic CD5 <sup>+</sup> B Cell Viability	201
<b>Figure 5.11:</b> Long Term Effects of Cytokines on Apoptosis of Leukemic CD5 <sup>+</sup> B Cell Apoptosis	204
<b>Figure 5.12:</b> Delaying the Addition of Viability-Enhancing Cytokines by 24-72 hours Abrogates their Effect	207
<b>Figure 5.13:</b> Optimisation of Anti-IL-2 and Anti-IL-4 Antiserum Concentrations	210
<b>Figure 5.14:</b> Leukemic CD5 <sup>+</sup> B Cells Must be Exposed to IL-2 or IL-4 for at Least 24 hours for these Cytokines to Have a Viability-Enhancing Effect.	213
<b>Figure 5.15:</b> Expression of bcl-2 by Cytokine-stimulated Leukemic CD5 <sup>+</sup> B Cells	220

## LIST OF TABLES

<b>Table 1.1:</b> Expression of antigens by Developing B Cells	6
<b>Table 3.1:</b> Optimal Concentrations of Activators for <i>In vitro</i> Stimulation of CLL B Cells	81
<b>Table 3.2:</b> IgM Secreted by Mitogen-Stimulated CLL PBLs is Monoclonal	92
<b>Table 3.3:</b> Anti- $\mu$ Does Not Synergise with PMA to Enhance Cell Viability Induced by PMA	116
<b>Table 3.4:</b> Secretion of IgM By MIL Leukemic CD5 <sup>+</sup> B cells Following Preactivation with PMA and/or anti- $\mu$	118
<b>Table 4.1:</b> Phenotype of Purified Leukemic CD5 <sup>+</sup> B Cells	137
<b>Table 4.2:</b> <i>In vitro</i> Half-lives of Leukemic CD5 <sup>+</sup> B Cells	139
<b>Table 4.3:</b> Effect of Oligonucleotides on Viability and Expression of Bcl-2 by Leukemic CD5 <sup>+</sup> B Cells	162
<b>Table 5.1:</b> Optimal Viability-Enhancing Concentrations of Cytokines for <i>In vitro</i> Cultured Leukemic CD5 <sup>+</sup> B Cells	183
<b>Table 5.2:</b> TNF- $\alpha$ and IL-6 Combine to Further Enhance the Viability of MUR B Cells.	199
<b>Table 5.3:</b> Effect of Anti-IL-10 on Leukemic CD5 <sup>+</sup> B Cell Viability	216
<b>Table 5.4:</b> Cytokines Do Not Induce Proliferation of Leukemic CD5 <sup>+</sup> B Cells	216
<b>Table 5.5:</b> Cytokines Do Not Enhance RNA Synthesis of Leukemic CD5 <sup>+</sup> B Cells	216

## Abbreviations

AET	2-aminoethyisothiuronium bromide
Ag	antigen
AML	acute myeloid leukemia
BCIP	bromochloroindolphenyl
B-CLL	B cell chronic lymphocytic leukemia
bp	base pairs
BSA	bovine serum albumin
BSF-MP6	B cell stimulatory factor derived from a T cell hybridoma
C	constant
cIg	cytoplasmic Ig
°C	degrees Celsius
CD	cluster of differentiation
CD40L	ligand for CD40
CLL	chronic lymphocytic leukemia
CD	cluster of differentiation
CIAA	chloroform isoamylalcohol
CPM	counts per minute
ELISA	enzyme-linked immunosorbant assay
EBV	Epstein Barr virus
FACS	fluorescence activated cell sorter
F(ab') <sub>2</sub> anti-μ	F(ab') <sub>2</sub> fragments of rabbit polyclonal Ig specific for human μ chains of IgM
FBS	fetal bovine serum
FcR	Fc receptor
FITC	fluorescein isothiocyanate
FSC	forward angle light scatter
H	Ig heavy chain

HCL	hairy cell leukemia
HIGM-1	hyper IgM immunodeficiency syndrome
IFN	interferon
Ig	immunoglobulin
IgA	immunoglobulin A
IgD	immunoglobulin D
IgE	immunoglobulin E
IgG	immunoglobulin G
IgM	immunoglobulin M
IL	interleukin
kDa	kilodalton
L	Ig light chain
LMW-BCGF	low molecular weight B cell growth factor
LPS	lipopolysaccharide
mAb	monoclonal antibody
MFI	mean fluorescence intensity
mins	minutes
μL	microlitre
mL	millilitre
NBT	nitroblue tetrazolium
NK	natural killer
nm	nanometre
pNPP	p-nitrophenyl phosphate
PBL	peripheral blood lymphocytes
PBS	phosphate buffered saline
PBS-BSA	0.1% BSA prepared in PBS, containing 0.1% sodium azide
PE	phycoerythrin
PHA	phytohemagglutinin

PKC	protein kinase C
PLL	prolymphocytic leukemia
PMA	phorbol myristic acetate
PMA <sub>low</sub>	a suboptimal, submitogenic concentration of PMA
PMA <sub>opt</sub>	optimal concentration of PMA
PWM	pokeweed mitogen
rpm	revolutions per minute
SAC	<i>Staphylococcus aureus</i> Cowan I
SCID	severe combined immunodeficiency
s.d.	standard deviation
SDS	sodium dodecyl sulfate electrophoresis
SDS-PAGE	sodium dodecyl sulfate polyacrylamide gel electrophoresis
s.e.m.	standard error of the mean
sIg	surface immunoglobulin
SRBC	sheep red blood cells
SSC	side (90°) light scatter
ssDNA	single stranded DNA
TBS	tris buffered saline
TBS-T	tris buffered saline containing 0.05% Tween
TGF	transforming growth factor
TNF	tumor necrosis factor
TNF-R	tumor necrosis factor receptor
TPA	tetradodecanoyl phorbol acetate
U	units
V	variable
XID	x-linked immunodeficiency